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Haiti: a case-control study and bias-indicator analysis
Louise C Ivers, Isabelle J Hilaire, Jessica E Teng, Charles P Almazor, J Gregory Jerome, Ralph Ternier, Jacques Boncy, Josiane Buteau, Megan B Murray, 
Jason B Harris, Molly F Franke
Summary
Background Between April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral 
inactivated bivalent whole-cell vaccine. We aimed to assess the eﬀ ectiveness of the vaccine in a case-control study and 
to assess the likelihood of bias in that study in a bias-indicator study.
Methods Residents of Bocozel or Grand Saline who were eligible for the vaccination campaign (ie, age ≥12 months, 
not pregnant, and living in the region at the time of the vaccine campaign) were included. In the primary case-control 
study, cases had acute watery diarrhoea, sought treatment at one of three participating cholera treatment units, and 
had a stool sample positive for cholera by culture. For each case, four control individuals who did not seek treatment 
for acute watery diarrhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and 
age (1–4 years, 5–15 years, and >15 years). Cases in the bias-indicator study were individuals with acute watery 
diarrhoea with a negative stool sample for cholera. Controls were selected in the same manner as in the primary 
case-control study. Trained staﬀ  used standard laboratory procedures to do rapid tests and stool cultures from study 
cases. Participants were interviewed to collect data on sociodemographic characteristics, risk factors for cholera, and 
self-reported vaccination. Data were analysed by conditional logistic regression, adjusting for matching factors.
Findings From Oct 24, 2012, to March 9, 2014, 114 eligible individuals presented with acute watery diarrhoea and were 
enrolled, 25 of whom were subsequently excluded. 47 participants were analysed as cases in the vaccine eﬀ ectiveness 
case-control study and 42 as cases in the bias-indicator study. 33 (70%) of 47 cholera cases self-reported vaccination 
versus 167 (89%) of 188 controls (vaccine eﬀ ectiveness 63%, 95% CI 8–85). 27 (57%) of 47 cases had certiﬁ ed 
vaccination versus 147 (78%) of 188 controls (vaccine eﬀ ectiveness 58%, 13–80). Neither self-reported nor veriﬁ ed 
vaccination was signiﬁ cantly associated with non-cholera diarrhoea (vaccine eﬀ ectiveness 18%, 95% CI –208 to 78 by 
self-report and –21%, –238 to 57 by veriﬁ ed vaccination).
Interpretation Bivalent whole-cell oral cholera vaccine eﬀ ectively protected against cholera in Haiti from 4 months to 
24 months after vaccination. Vaccination is an important component of eﬀ orts to control cholera epidemics.
Funding National Institutes of Health, Delivering Oral Vaccines Eﬀ ectively project, and Department of Global Health 
and Social Medicine at Harvard Medical School.
Copyright © Ivers et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Cholera epidemics continue to cause major morbidity and 
mortality globally, and recent large outbreaks in Haiti, 
Zimbabwe, and Sierra Leone1–3 show the urgent need for 
improved control measures to save lives and reduce 
human suﬀ ering. Two oral cholera vaccines are pre-
qualiﬁ ed for use by WHO: a bivalent inactivated vaccine 
containing killed whole cells of Vibrio cholerae O1 and 
V cholerae O139 (bivalent whole-cell vaccine), marketed as 
Shanchol (Shantha Biotechnics, Hyderabad, India), and 
an inactivated vaccine containing killed whole cells of 
V cholerae O1 with recombinant B subunit of cholera toxin, 
marketed as Dukoral (Crucell, Stockholm, Sweden). 
Although oral cholera vaccines were safe and eﬀ ective in 
large trials,4–7 and WHO has recommended consideration 
of their use in epidemics, they are not routinely used in 
cholera outbreaks.8 This is a result of several factors,9 not 
least of which is the scarcity of data on the eﬀ ectiveness of 
the vaccines in real-life settings, especially during the 
complex situation of a cholera epidemic.10 In Guinea and 
Haiti in 2012, large-scale reactive oral cholera vaccine 
campaigns with bivalent whole-cell vaccine contributed to 
increased understanding of the use of oral cholera vaccines 
in epidemic settings.11,12
10 months after an earthquake near the capital city 
of Port-au-Prince resulted in a massive humanitarian 
disaster,13 a major cholera epidemic began in central 
Haiti in October, 2010, and rapidly spread throughout the 
country within 1 month.3 The Haitian National Public 
Health Laboratory identiﬁ ed V cholerae serogroup O1 
biotype El Tor as the cause of the epidemic by culture of 
stool specimen.3 By December, 2014, 720 524 people in 
Haiti were reported to have had cholera, of whom 
407 147 were admitted to hospital and 8774 died, with 
unmeasured social and ﬁ nancial costs.14,15 Cholera had 
never been reported in Haiti before this outbreak.
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In response to this cholera epidemic, from April to June, 
2012, we undertook an oral cholera vaccination campaign 
with bivalent whole-cell vaccine, in partnership with the 
Haitian Ministry of Health. By the time the vaccination 
campaign began, the cholera epidemic had been ongoing 
for 17 months in Haiti, and reported weekly case incidence 
remained as high as 123·5 cases per 10 000 population 
in some regions of the country.14 45 417 people were 
vaccinated in the campaign, 91% of whom received both 
doses of the two-dose vaccination schedule.12,16 We 
subsequently undertook a case-control study to assess the 
eﬀ ectiveness of the vaccine and a bias-indicator study to 
assess the likelihood of bias in the eﬀ ectiveness study.
Methods
Study design and participants
We undertook two matched case-control studies. In the 
primary study, we aimed to examine the eﬀ ectiveness of 
oral cholera vaccination. The second case-control study 
was a bias-indicator study in which we assessed the 
likelihood of bias in the primary case-control study by 
examining the relation between vaccination and 
non-cholera diarrhoea.17
The studies were done in the Artibonite Department of 
Haiti, in three health centres that provide primary health 
services to the regions of Bocozel and Grand Saline. 
Bocozel and Grand Saline are rural, rice-growing regions 
of the country that are irrigated by branches of the 
Artibonite River, without which they are dry and desert 
like. Located about 120 km from Port-au-Prince, they have 
a combined population of about 55 000 people and were 
targeted by the oral cholera vaccine campaign between 
April and June, 2012. These regions are served by a 150-
bed Ministry of Health hospital, L’Hôpital St Nicolas, 
which is supported by the non-governmental organisation 
Partners In Health and by two dispensaries, one in each 
of the isolated communities of Grand Saline and Bocozel. 
An estimated 77–93% of the Bocozel community and 63% 
of the Grand Saline community were vaccinated against 
cholera in the 2012 campaign.12 The vaccination campaign 
is described in detail elsewhere.12
Enrolment into the studies began 4 months after the 
vaccination campaign ended. For both studies, eligible 
participants were residents of Bocozel or Grand Saline 
at the start of the studies who were eligible for the 
vaccination campaign (ie, age ≥12 months, not pregnant, 
and living in the region at the time of the vaccine 
campaign). Resident was deﬁ ned as eating and sleeping 
in a household in the location over 50% of the time.
We recruited study participants at the three health 
centres, and we trained community health workers in 
the region to undertake surveillance and refer acute 
watery diarrhoea cases to the health centre, after 
initiating oral rehydration as appropriate. We enrolled 
individuals with acute watery diarrhoea—deﬁ ned as 
three or more loose, non-bloody, liquid stools in a 24-h 
period with an onset of 3 days or fewer before 
presentation—who sought treatment at any of the 
three study sites and met all eligibility criteria. 
Participants were asked to provide a stool sample for 
testing by the Crystal VC rapid test (Span Diagnostics, 
Gujarat, India, hereafter referred to as the rapid test) and 
by culture. Cases were later classiﬁ ed as either cholera 
cases or non-cholera cases based on the results of the 
rapid test and culture.
Cases in the vaccine eﬀ ectiveness study were 
individuals with a stool sample positive for V cholerae O1 
by culture. Controls were individuals who did not seek 
treatment for diarrhoea between the ﬁ rst day of study 
enrolment and the date of onset of symptoms in their 
corresponding case. Four controls were matched to each 
case by location of residence, enrolment time (within 
2 weeks of the case), and age (1–4 years, 5–15 years, and 
>15 years).18 When more than one eligible control was 
available in a household, an individual of the same sex 
Figure 1: Proﬁ le of study cases
*Approximate, based on clinic reporting.
1034 individuals with acute watery diarrhoea 
 screened for eligibility based on residence
 418 at Hospital Saint Nicolas
 453 at Bocozel Clinic*
 163 at Grand Saline Clinic*
32 excluded
 4 declined participation
 28 ineligible
 10 lived outside catchment area
 4 were pregant during the 
  vaccination campaign
 2 were <1 year old during the 
  vaccination campaign
 6 had bloody or chronic diarrhoea
 6 reason unknown
24 excluded
 16 rapid test positive and culture 
  negative
 8 no specimen for culture
48 stool culture positive; classiﬁed as cases in the 
  vaccine eﬀectiveness study
42 rapid test negative and stool culture negative; 
  classiﬁed as cases in the bias-indicator study
47 cases included in analyses of vaccine eﬀectiveness 
1 excluded 
 1 data lost
42 cases included in analyses of bias
146 individuals with diarrhoea invited to participate
114 individuals with acute watery diarrhoea enrolled
888 did not meet criteria
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was selected where possible. If more than one eligible 
control was available but they were both of diﬀ erent sex 
to the case, the one most closely matching the case in age 
was chosen. In rural Haiti, households are often grouped 
in a cluster of multigenerational families called “lakou”.19 
In choosing controls, study workers approached the 
home nearest to the case’s home, excluding homes 
within the same lakou because we anticipated that 
exposure to the cholera vaccine was likely to be highly 
correlated within the lakou. Study workers then 
approached the next closest residence and so on until 
four matched controls were enrolled.
Cases in the bias-indicator study were individuals with 
acute watery diarrhoea with a stool sample that tested 
negative for cholera by both the rapid test and culture. 
Controls were selected in the same manner as in the 
primary case-control study. Because the vaccine was not 
expected to provide protection against non-cholera 
diarrhoea, in the absence of bias we expected a null 
association between vaccination and non-cholera 
diarrhoea in the bias-indicator case-control study.17,20,21
Ethical approval for these studies was obtained from 
Partners Institutional Review Board (Boston, MA, USA) 
and the Haitian National Bioethics Committee 
(Port-au-Prince, Haiti). The vaccination campaign itself 
was a public health campaign directed by the Ministry of 
Health and Population of Haiti, implemented by Partners 
In Health and GHESKIO, and approved by the Haitian 
Bioethics Committee. Informed consent for vaccination 
was not required during the campaign, but all participants 
in the research studies signed informed consent before 
participation. For those participants who were unable to 
consent (eg, those who were too unwell), a health-care 
proxy was permitted to provide consent to participate. 
Consent from a parent or guardian was obtained for 
children under 18 years of age. Additionally, assent was 
sought from children aged 7–17 years.
Procedures
Trained staﬀ  used standard laboratory procedures to do 
rapid tests and stool cultures from study cases, and results 
were recorded in the study register. The stool samples 
were collected in sterile containers, and rapid tests were 
done immediately according to the manufacturer’s 
protocol. An additional specimen was transported in 
Cary-Blair media to the Haitian National Public Health 
Laboratory in Port-au-Prince for subsequent culture 
on thiosulfate-citrate-bile salts-sucrose. Identiﬁ cation of 
V cholerae serogroup O1 at the serotype level was done 
using a standard slide agglutination method.22
To collect data on sociodemographic characteristics, risk 
factors for cholera, and self-reported vaccination, study 
workers interviewed participants at the cholera treatment 
unit at enrolment. For participants younger than 18 years 
and those who were unavailable for interview, guardians 
or a family member proxy responded to questions on 
behalf of the participant. Individuals who reported receipt 
of at least one dose of the vaccine were asked to produce 
their vaccine card as veriﬁ cation at a home visit within 
2 weeks of enrolment. Vaccination registries were used to 
verify vaccination status for individuals who reported 
vaccination but could not produce a vaccine card or who 
reported no vaccination. A study worker reviewed the 
clinical charts of conﬁ rmed cholera cases.
Cholera diarrhoea 
cases (n=48)
Non-cholera diarrhoea 
cases (n=41)*
Time from symptom onset to admission (days) 0 (0–1) 0 (0–1)
Serotype
Ogawa 37 (77%) NA
Inaba 11 (23%) NA
Dehydration stage at presentation
A (mild) 0 (0%) 10 (24%)
B (moderate) 22 (46%) 25 (61%)
C (severe) 26 (54%) 6 (15%)
Treatment received at clinic
Oral rehydration solution 46 (96%) 39 (95%)
Intravenous ﬂ uids 46 (96%) 29 (71%)
Antibiotics 9 (19%) 2 (5%)
Volume of oral rehydration solution given in clinic (L)† 10 (6–14) 2 (2–5)
Volume of intravenous ﬂ uid given in clinic (L)‡ 15 (9–20) 3 (2–6)
Admitted overnight to the cholera treatment unit 48 (100%) 29 (71%)
Duration of stay at cholera treatment unit (days) 3 (2–4) 1 (0–1)
Outcome
Discharged 45 (94%) 38 (93%)
Transferred 1 (2%) 0 (0%)
Died 1 (2%) 0 (0%)
Left against medical advice 1 (2%) 3 (7%)
Data are median (IQR) or number (%). NA=not applicable. *Clinical data were missing for one of 42 non-cholera diarrhoea 
cases. †Among those given oral rehydration solution (46 cholera diarrhoea cases and 36 non-cholera diarrhoea cases). 
‡Among those given intravenous ﬂ uids (46 cholera diarrhoea cases and 29 non-cholera diarrhoea cases).
Table 1: Clinical presentation and treatment of cholera cases
Figure 2: Timeline of presentation of cases of cholera and non-cholera acute watery diarrhoea
Cases were classiﬁ ed based on culture results; where culture results were not available (n=8), they were classiﬁ ed 
based on rapid test results. Depicted rainy seasons are based on historical mean rainfall, not actual rainfall.
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Statistical analysis
We analysed data by conditional logistic regression, 
adjusting for matching factors. Models included a measure 
of vaccination status: self-reported vaccination with at least 
one dose, number of self-reported doses, or documented 
vaccination with at least one dose per vaccine card or 
registry review. Multivariable models were adjusted for sex 
as a discrete variable and age as a continuous variable 
because we used broad age categories to match cases and 
controls according to age. We also adjusted for variables 
that were associated with both vaccination and cholera (or 
non-cholera diarrhoea in the bias-indicator study) at a 
p value of less than 0·20 (ie, potential confounders). 
Eﬀ ectiveness of the vaccine was calculated using the vaccine 
Cholera vaccine eﬀ ectiveness case-control 
study
Bias-indicator case-control study
Cholera 
diarrhoea 
cases (n=47)
Controls (n=188) p value* Non-cholera 
diarrhoea 
cases (n=42)
Controls (n=168) p value*
Age (years) 27 (13–43) 30·5 (9·5–44·5) ··† 31·5 (20–45) 34 (18·5–48) ··†
Sex
Male 31 (66%) 91 (48%) ·· 16 (38%) 66 (39%) ··
Female 16 (34%) 97 (52%) 0·010 26 (62%) 102 (61%) 0·82
Participant responded to interview (vs proxy) 30 (64%) 136 (72%) 0·012 35 (83%) 133 (79%) 0·26
Earthen ﬂ oor in home (vs cement or wood) 36 (77%) 141 (75%) 0·77 35 (83%) 112 (67%) 0·021
Ever attended school 22 (47%) 112 (60%) 0·088 28 (67%) 110 (65%) 0·88
House has electricity 8 (17%) 19 (10%) 0·045 6 (14%) 23 (14%) 0·86
Number of people in household 5 (3–7) 5 (4–6) 0·42 5 (3–6) 5 (3–7) 0·88
Agriculture is the main income-generating activity 29 (62%) 109 (58%) 0·59 22 (52%) 100 (60%) 0·35
Main toilet is a latrine (vs unimproved or open defecation) 29 (62%) 90 (48%) 0·043 26 (62%) 95 (57%) 0·48
Ever admitted overnight to a cholera treatment unit‡ 6 (17%) 20 (14%) 0·66 5 (13%) 19 (12%) 0·91
Household member with cholera in the past week 2 (4%) 3 (2%) 0·28 2 (5%) 2 (1%) 0·15
Household member ever spent a night in a cholera treatment unit 17 (36%) 50 (27%) 0·19 17 (40%) 57 (34%) 0·41
Household member with diarrhoea in the past week 8 (17%)§ 18 (10%) 0·12 4 (10%) 11 (7%) 0·49
Data are median (IQR) or number (%). *Univariable conditional logistic regression adjusted for matching factors. †Cases and controls were matched by age; therefore, no 
p value is provided. ‡For the cholera case-control study, data were available for 35 cases and 140 controls. For the non-cholera diarrhoea case-control study, data were 
available for 39 cases and 160 controls. §Data were available for 46 cases.
Table 2: Characteristics of cholera cases, non-cholera diarrhoea cases, and controls
Cases Controls Crude RR* (95% CI) Adjusted RR (95% CI) Vaccine eﬀ ectiveness 
(95% CI)
p value 
Cholera vaccine eﬀ ectiveness case-control study
Vaccinated, self-report 33/47 (70%) 167/188 (89%) 0·27 (0·12–0·61) 0·37 (0·15–0·92)† 63% (8 to 85) 0·031
Number of self-reported doses
None 14/47 (30%) 21/188 (11%) Reference Reference ·· ··
One 3/47 (6%) 19/188 (10%) 0·20 (0·05–0·87) 0·33 (0·07–1·62)† 67% (–62 to 93) 0·17
Two 30/47 (64%) 148/188 (79%) 0·28 (0·13–0·63) 0·38 (0·15–0·94)† 62% (6 to 85) 0·036
Proof of vaccination (card or 
registry record)
27/47 (57%) 147/188 (78%) 0·35 (0·17–0·72) 0·42 (0·20–0·87)‡ 58% (13 to 80) 0·020
Bias-indicator case-control study
Vaccinated, self-report 39/42 (93%) 158/168 (94%) 0·83 (0·22–3·09) 0·82 (0·22–3·08)‡ 18% (–208 to 78) 0·77
Number of self-reported doses
None 3/42 (7%) 10/168 (6%) Reference Reference
One 7/42 (17%) 11/168 (7%) 2·50 (0·47–13·25) 2·53 (0·48–13·37)‡ –153% (–1237 to 52) 0·28
Two 32/42 (76%) 147/168 (88%) 0·73 (0·19–2·78) 0·72 (0·19–2·74)‡ 28% (–174 to 81) 0·63
Proof of vaccination (card or 
registry record)
36/42 (86%) 137/168 (82%) 1·39 (0·52–3·70) 1·21 (0·43–3·38)§ –21% (–238 to 57) 0·72
Data are number (%), unless otherwise speciﬁ ed. Some percentages do not total 100 because of rounding. RR=relative risk. *Adjusted for matching factors. †Adjusted for 
matching factors, female sex, age (continuous), electricity in the home, main toilet type, and whether the participant completed the interview (vs a proxy). ‡Adjusted for 
matching factors, female sex, and age (continuous). §Adjusted for matching factors, female sex, age (continuous), and earthen ﬂ oor in the household.
Table 3: Eﬀ ectiveness of the oral cholera vaccine in rural Haiti
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eﬀ ectiveness formula: vaccine eﬀ ectiveness=(1 – relative 
risk).23 We used a likelihood ratio test to examine whether 
there was a linear dose–response relation between the 
number of vaccine doses received and eﬀ ectiveness. We 
examined whether cholera vaccine eﬀ ectiveness varied by 
time since vaccination (before vs on or after July 1, 2013, 
about 1 year after the completion of the vaccination 
campaign), age group (<5 years vs ≥5 years), previous 
admission to a cholera treatment unit, and severity of 
dehydration. We included an interaction term between the 
potential modiﬁ er and any self-reported vaccination. 
Because of small sample sizes in subgroups, we reported 
ratios adjusted for matching factors only.
Role of the funding source
The funders of the studies had no role in study design, 
study execution, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all data in the studies and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
From Oct 24, 2012, to March 9, 2014, 114 eligible 
individuals presented with acute watery diarrhoea and 
were enrolled (ﬁ gure 1). Of these, 48 were conﬁ rmed to 
have cholera by culture and therefore were cases in 
the primary case-control study of cholera vaccine 
eﬀ ectiveness. One participant with cholera was 
subsequently excluded from analysis of vaccine 
eﬀ ectiveness when electronic interview data were lost 
because of a technology malfunction. 42 individuals were 
conﬁ rmed not to have cholera by a negative rapid test and 
culture and therefore were analysed as cases in the bias-
indicator study. Participants with diarrhoea with and 
without cholera were geographically dispersed throughout 
the study area, with most recruited cases residing in 
Bocozel and southern Grand Saline.
Among the 48 participants with cholera, presentation to 
the clinic usually occurred within 1 day of symptom onset 
and more than half of cases had severe (grade C) 
dehydration (table 1). Median stay at the cholera treatment 
unit was 3 days (IQR 2–4). Figure 2 displays the timeline 
of presentation of cholera and non-cholera cases during 
the study period. Cholera cases seemed to be more 
frequent at times that corresponded to the rainy season.
Table 2 lists characteristics of cases and controls in both 
studies. In the primary case-control study, participants 
with cholera were less likely than controls to be female 
(p=0·010) and to have completed the interview 
themselves (p=0·012). Compared with controls, partici-
pants with cholera were more likely to have electricity in 
their home (p=0·045) and to have a latrine as their main 
toilet type (p=0·043).
70% of cholera cases and 89% of controls self-reported 
vaccination, and we veriﬁ ed vaccination in 57% of cholera 
cases and 78% of controls (table 3). Among those 
vaccinated, most received both vaccine doses (table 3). In 
univariate analyses adjusted for matching factors, both 
any self-reported vaccination (relative risk 0·27, 95% CI 
0·12–0·61) and any vaccination veriﬁ ed through vaccine 
card or registry (0·35, 0·17–0·72) were associated with a 
signiﬁ cant reduction in the risk of cholera (table 3). In 
multivariable analyses, vaccine eﬀ ectiveness was 63% 
(95% CI 8–85) by self-report and 58% (13–80) for 
vaccination veriﬁ ed through the card or registry. We 
examined whether protection increased with each dose of 
the vaccine. Although one dose of vaccine was not 
associated with a signiﬁ cantly lower rate of cholera than no 
vaccine, only a small number of individuals received a 
single dose and we could not rule out the possibility of a 
linear relation between the number of doses and 
eﬀ ectiveness on the basis of the likelihood ratio test 
(likelihood ratio p value=0·67). We did not identify 
an interaction between the vaccine and age group 
(pinteraction=0·70), severity of dehydration (pinteraction=0·94), time 
since vaccination (pinteraction=0·29), or previous admission to 
a cholera treatment unit (pinteraction=0·35; table 4).
In the bias-indicator study, nearly all non-cholera 
diarrhoea cases (93%) and controls (94%) self-reported 
receipt of at least one dose of vaccine (table 3). Vaccination 
with at least one dose of vaccine was veriﬁ ed in 86% of 
cases and 82% of controls. Neither self-reported nor 
veriﬁ ed vaccination was signiﬁ cantly associated with 
non-cholera diarrhoea in univariate (relative risk 0·83, 
95% CI 0·22–3·09 and 1·39, 0·52–3·70, respectively) or 
multivariable analyses (vaccine eﬀ ectiveness 18%, 
95% CI –208 to 78 and –21%, –238 to 57, respectively; 
table 3).
Discussion
The bivalent whole-cell vaccine was eﬀ ective in reducing 
the rate of cholera among vaccine recipients in rural 
Haiti between 4 months and 24 months (ie, from April, 
Cholera 
cases 
(n=47)
Controls 
(n=188)
Crude RR for self-
reported vaccination* 
(95% CI)
Vaccine 
eﬀ ectiveness 
(95% CI)
pinteraction
Age
<5 years 9 (19%) 31 (16%) 0·50 (0·03 to 9·46) 50% (–850 to 97) 0·70
≥5 years 38 (81%) 157 (84%) 0·28 (0·12 to 0·64) 72% (36 to 88) ··
Dehydration stage at presentation
B (moderate) 21 (45%) NA 0·28 (0·08 to 0·97) 72% (3 to 92) 0·94
C (severe) 26 (55%) NA 0·27 (0·09 to 0·77) 73% (23 to 91) ··
Time since vaccination
<1 year 12 (26%) 49 (26%) 0·13 (0·02 to 0·68) 87% (32 to 98) 0·29
≥1 year 35 (74%) 139 (74%) 0·36 (0·14 to 0·90) 64% (10 to 86) ··
Previous admission to a cholera treatment unit†
Yes 6 (17%) 20 (14%) 1·03 (0·08 to 12·61) –3% (–1161 to 92) 0·35
No 29 (83%) 120 (86%) 0·29 (0·11 to 0·79) 71% (21 to 89) ··
Data are number (%), unless otherwise speciﬁ ed. NA=not applicable. RR=relative risk. *Adjusted for matching factors. 
†Data available for 35 cases and 140 controls.
Table 4: Subgroup analyses of eﬀ ectiveness of the oral cholera vaccine
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2012, to March, 2014) after vaccination began (panel). 
Vaccine eﬀ ectiveness was similar to Sur and colleagues’6 
estimate of a 2-year eﬀ ectiveness of the same vaccine of 
67% in India, a historically cholera-endemic region. This 
similarity might be because the vaccine was administered 
in Haiti after many months of protracted transmission.
Our ﬁ ndings address the substantial knowledge gap 
surrounding the use of oral cholera vaccines in reactive 
vaccination in populations that have had limited 
endemic exposure to cholera.8 Such populations are 
most at risk of explosive epidemics once cholera 
emerges. A study from the reactive oral cholera 
vaccination campaign in Guinea in 201211 showed that 
bivalent whole-cell vaccine oﬀ ered signiﬁ cant early 
protection against cholera at 6 months (eﬀ ectiveness 
86·6%, 95% CI 56·7–95·7; p=0·001). The present 
ﬁ ndings suggest that reactive vaccination was eﬀ ective 
in a population with no historical exposure or immunity 
to cholera and in the midst of the worst cholera epidemic 
of the past decade. Furthermore, our ﬁ ndings extend the 
ﬁ ndings of the Guinea study,11 showing that the beneﬁ t 
of vaccination extends beyond 6 months to 2 years after 
vaccination. Our results are also consistent with our 
previous ﬁ nding29 that seroconversion rates among 
Haitian vaccine recipients were robust and comparable 
to those of Bangladeshis who had also received two 
doses of the vaccine.
Analysis of data from a placebo-controlled trial 
of recombinant cholera-toxin B subunit vaccine in 
Bangladesh30 showed that vaccination provided 
signiﬁ cant herd protection to neighbouring non-
vaccinated indi viduals. In our previous study,12 
community coverage in the region targeted by the 
vaccination campaign, which was also where the study 
sites were located, was between 62·5% and 92·7%. This 
coverage is more than is believed to be needed for 
signiﬁ cant herd immunity.30 We also previously showed 
that the vaccination campaign in Haiti was associated 
with signiﬁ cant improvements in knowledge of cholera 
and practices related to waterborne disease,31 suggesting 
additional indirect beneﬁ ts associated with vaccination.
The present observational studies have some limitations. 
We assessed vaccine exposure through self-report, and we 
veriﬁ ed vaccination through documentation of the vaccine 
card or registration in the vaccine registry. Neither of these 
assessments is perfect: self-reported vaccination might be 
aﬀ ected by a cholera episode and therefore might diﬀ er by 
case or control status, whereas lost vaccine cards and 
misspelled names might lead to underestimates of 
vaccination coverage. However, despite these limitations, 
we noted consistent, robust estimates of vaccine 
eﬀ ectiveness in the order of 58–63% using two vaccination 
assessments with errors that are unlikely to be linked. The 
small number of cases in the vaccine eﬀ ectiveness study 
limited the power for subgroup and dose–response 
analyses, which merit examination in larger studies. We 
assessed the likelihood of bias in the vaccine eﬀ ectiveness 
case-control study and found no association between 
vaccination and non-cholera diarrhoea, which supports 
the validity of our ﬁ ndings.
Now in its ﬁ fth year, the cholera epidemic in Haiti has 
decelerated in terms of case incidence, but continues to 
cause substantial morbidity and mortality. More than 
58 500 cases were registered in 2013 alone, and between 
Jan 8, 2014, and Dec 8, 2014, 22 668 cases and 240 deaths 
were reported.14 The epidemic subsequently spread from 
Haiti to other countries in the region, including the 
Dominican Republic, Cuba, and Mexico.32 The rapid 
evolution of this epidemic and its toll on human life and 
on the health system of Haiti have reinforced the need 
for improved methods for control of cholera 
in the country. Investment in water and sanitation 
infrastructure in Haiti will have a widespread eﬀ ect on 
improving health and is the cornerstone of a binational 
plan to eliminate cholera from Hispaniola.33 However, in 
Panel: Research in context
Systematic review
Before planning the present studies, we searched PubMed on Dec 10, 2011, for articles 
with the search terms “oral cholera vaccine”, “cholera”, “vaccine eﬀ ectiveness”, “vaccine 
eﬃ  cacy”, and “case control”. This search yielded 147 records, from which we identiﬁ ed 
12 relevant studies, many of which were also included in a Cochrane review of oral cholera 
vaccine studies.24 We also identiﬁ ed relevant articles and studies from agencies and 
resources such as WHO, the Haitian Ministry of Health website (articles in French), NIH 
RePORTER, and ClinicalTrials.gov. Three additional papers were published after our studies 
began.4,10,11 Two case-control studies done in Mozambique20 and Zanzibar25 using a 
recombinant cholera-toxin B subunit vaccine showed 78% and 79% protection against 
cholera, respectively. In the Mozambique study,20 vaccine eﬀ ectiveness did not diﬀ er 
between those younger than 5 years or those aged 5 years or older.20 In trials done in 
endemic settings, eﬀ ectiveness of the same oral cholera bivalent whole-cell vaccine that 
we studied was 65% in India5 and about 50% in Bangladesh26 at 3 years of follow-up. In 
outbreak settings, a killed whole-cell vaccine produced in Vietnam (ORCvax) had 76% 
protection,27 and a bivalent whole-cell vaccine had 86·6% protection at 6 months in 
Guinea.11 In Peru, recombinant cholera-toxin B subunit oral cholera vaccine had 61–72% 
protective eﬃ  cacy at 24-month follow-up, with better protection in those aged 15 years 
and older than in those younger than 15 years.28 In a follow-up4 of the Indian study,5 the 
vaccine sustained a cumulative 65% protective eﬃ  cacy at 5 years.
Interpretation
In our case-control studies of bivalent whole-cell oral cholera vaccine in a protracted 
epidemic in Haiti, vaccination was protective against cholera for up to 2 years of 
follow-up. Our studies show that oral cholera vaccine is eﬀ ective in an epidemic setting; 
most previous evidence on oral cholera vaccine eﬀ ectiveness has been collected in 
endemic settings such as India and Bangladesh. Our ﬁ ndings in the context of previously 
published work suggest that oral cholera vaccine can be used as an instrument to 
complement case ﬁ nding, treatment, and clean water and hygeine initiatives in the 
response to cholera outbreaks and can reduce the burden of cholera in protracted 
epidemic settings. Continued follow-up should be done to ascertain longer-term vaccine 
eﬀ ectiveness in epidemics, especially in populations, such as that in our studies, that do 
not have historic exposure to endemic cholera. Further research is also warranted to 
understand the eﬀ ectiveness of one dose of vaccine, the safety and eﬀ ectiveness of the 
vaccine in pregnancy, and the heat stability of the vaccine, all of which would improve the 
ease with which mass vaccination campaigns could be undertaken.
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addition to intermediate-term and long-term water and 
sanitation interventions, new approaches to disease 
control are urgently needed. Our ﬁ ndings contribute to 
mounting evidence that oral cholera vaccines have an 
important part to play as a component of comprehensive, 
integrated cholera control eﬀ orts in Haiti.
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